GlassScriptPhysician profile
Ethan J Brown
NPI 1255115762
$4,127.21
in general payments reported to CMS, 2019-2025
26 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $106 · 2024: $1,830 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,127.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.70 | 2024-2025 | |
| Janssen Biotech, INC. | $596.45 | 2024-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $373.83 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.67 | 2024-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $226.80 | 2024-2025 | Dupixent |
| Genzyme Corporation | $187.76 | 2024-2025 | |
| Madrigal Pharmaceuticals | $147.63 | 2024-2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $143.71 | 2024-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $115.46 | 2024-2025 | Omvoh |
| Pfizer INC. | $106.10 | 2024-2025 | |
| Ardelyx, INC. | $76.90 | 2024-2025 | Ibsrela |
| Biosense Webster, INC. | $76.21 | 2023-2024 | Carto 3 |
| Ironwood Pharmaceuticals, INC | $65.58 | 2024 | |
| Inari Medical, INC. | $60.25 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardiva Medical, INC. | $55.92 | 2023-2024 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $52.54 | 2023-2025 | Symplicity G3, Arctic Front Advance, Ffrangio |
| Shield Therapeutics INC | $51.11 | 2024 | |
| Braintree Laboratories, INC. | $45.01 | 2025 | Suflave |
| Phathom Pharmaceuticals, INC. | $38.03 | 2024-2025 | Voquezna |
| Abiomed | $32.48 | 2024 | Impella |
| Qol Medical, LLC | $28.98 | 2024 | Sucraid |
| Albireo Pharma, INC. | $21.83 | 2024 | Iqirvo |
| Novo Nordisk INC | $16.69 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $13.88 | 2024 | |
| Merck Sharp & Dohme LLC | $13.56 | 2024 | Dificid |
| Organon LLC | $10.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.